Arrayjet are a leading bio-printing solutions provider with a global presence of instrument installations in 26 countries worldwide, and over 300 customers through its service facility. Its unique non-contact inkjet printing technology is the fastest, most accurate, consistent and reproducible available on the market. Full accessibility to customers is available through its in-house printing service 'Arrayjet Advance' and offers five scalable instruments from research & development to industrial scale manufacturing capabilities of up-to 1000 slide batches per print run.

Our Solutions

Our Customers

  • EMBL
  • The Human Protein Atlas
  • John Hopkins University
  • Sanger Institute
  • The United States Army Medical Research Institute for infectious diseases
  • CapitalBio Corporation
  • KEMRI Wellcome Trust
  • CDI Laboratories
  • University of Copenhagen
  • Avacta Life Sciences
  • "We are very pleased to be working with Arrayjet, as we see high throughput inkjet technology as very much the future of protein microarraying. The Super-Marathon enables us to do things that are simply not possible with a pin spotter, and we've given it pride of place in our new, highly automated facility."

    Alan Sawyer, Director at EMBL Monoclonal Core Facility
  • "Our Arrayjet Marathon has been instrumental in achieving the throughput and reliability that have been needed for production of antigen arrays for validation of 47,000 antibodies within the Human Protein Atlas. It has also shown to be highly suitable for production of our large scale arrays that comprises over 20,000 features per array in both antigen and reverse phase serum arrays. We have arrayed more than 12,000 slides with the Arrayjet Marathon over the last five years and it has become a very important part of our research group and the SciLifeLab National Affinity Proteomics protein array facility."

    Peter Nilsson, Principal Investigator, The Human Protein Atlas, Stockholm
  • "Arrayjet’s JetSpyder sample aspiration device effectively eliminates any cross contamination between protein samples, so the quality of our slides is significantly improved. Previously we could produce just over 150 slides of acceptable quality in a print run, too slow a pace for the scale and growth of current and future demands; being able to print up to 1000 slides quickly, in a highly efficient manner was incredibly appealing to us."

    Heng Zhu, Professor at Johns Hopkins School of Medicine, Baltimore
  • “Since becoming a user of a Marathon Inkjet Microarrayer, I have been extremely happy with the service and expertise provided by Arrayjet. Any questions about the technology are answered promptly by knowledgeable and friendly in-house scientists and support staff. The machine is easy to use and can print many samples quickly and accurately, which is perfect for any kind of high throughput methods development project!”

    Dr Laura Wood, Postdoctoral Researcher, Wellcome Trust Sanger Institute, Cambridge
  • "[The] Arrayjet's efficiency allows for fast array spotting that is also very reproducible. The high-capacity platform is helpful in producing multiple array slides per printing run. The software is user-friendly and the tech support has been nothing short of outstanding with any situations we have encountered."

    Dr Robert Ullrich, Principal Investigator, USAMRIID, Frederick
  • “I am impressed by the advanced technology and the innovative design of the Arrayjet Ultra Marathon II Microarrayer. We are glad to be the first user of the Arrayjet Ultra Marathon II Microarrayer with the camera module. Arrayjet constantly upgrades its products. This makes us optimistic about the prospect of long-term partnership with Arrayjet.”

    Dr. An Shuang, Head of Array Production, CapitalBio Corporation, Beijing
  • "The combination of an excellent product in their microarray printers and a responsive technical support team to assist with bespoke solutions to individual project needs were two of the many attributes that attracted us to work with Arrayjet. At every step of the design of an in-house microarray chip, we had at our disposal a dedicated team of application specialists who were very cordial and available to respond to our many queries. It was on the back of this excellent support that we eventually purchased one of their microarray printers and we have continued to enjoy excellent technical training on the instrument and engineering support."

    Dr. James Tuju, Principal Investigator, KEMRI Wellcome Trust, Kenya
  • "CDI Laboratories recently purchased an Arrayjet ‘Ultra Marathon II’ to print microarrays for our ‘HuProt’ product line, focussed arrays with smaller subset of proteins for discovery arrays and hybridoma project work. CDI are planning to print monoclonal arrays and membrane protein arrays with the new technology in the near future. Arrayjet’s technology was chosen as we needed to quintuple capacity, preferably with one Instrument, its hi-tech, precise and user friendly capabilities was an obvious benefit. One of the added advantages of the company structure is that they provide in-house printing through ‘Arrayjet Advance’ and we were able to carry out several studies over several months to reaffirm our belief that the technology would improve many facets of our operation."

    Dr Ignatio Pino, CEO, CDI Laboratories, Baltimore
  • "The production of microarrays of complex and diverse carbohydrates presents particular unique challenges. The Arrayjet Sprint works very well for this purpose and in our experience is superior to pin based printers. We have found that the Sprint is very fast, accurate and most important, able to handle polysaccharides and oligosaccharides with widely different chemical and physical properties. What is also impressive is that we are able to print extracted material directly without clean up, despite the fact that some extraction solvents are very harsh, for example 4 M sodium hydroxide.''

    Prof William Willats, University of Copenhagen
  • "Access to the Ultra-Marathon through Arrayjet Advance Services has allowed to us to explore product options that would otherwise be out of reach”.

    Paul Ko Ferrigno, CSO, Avacta Life Sciences Ltd, York